



TECO DIAGNOSTICS
 1268 N. Lakeview Ave.
 Anaheim, CA 92807
 1-800-222-9880

TRIGLYCERIDE REAGENT
TC MATRIX-240/480

INTENDED USE

The triglyceride test is used for the quantitative determination of triglyceride in human serum or plasma.

SUMMARY AND PRINCIPLE^{1, 2, 3, 4, 5}

Triglycerides are hydrolyzed by lipoprotein lipase to produce glycerol and free fatty acids. The glycerol participates in a series of coupled enzymatic reactions, in which glycerol kinase / glycerol phosphate oxidase are involved and H₂O₂ is generated. H₂O₂ reacts with p-chlorophenol and 4-aminoantipyrine in the presence of peroxidase to form a quinoneimine dye. The intensity of formed color is proportional to the triglycerides concentration and can be measured photometrically between 480 and 520 nm.

REAGENTS

Each kit contains:

Reagent:

4-chlorophenol	2.7 mM
4-AAP	0.3 mM
ATP	2 mM
GK	> 1000 U/L
POD	> 1000 U/L
LPL	> 2000 U/L
GPO	> 5000 U/L
Good's buffer pH 7.20	50 mM surfactants

REAGENT PREPARATION

Reagents are ready for use.

PRECAUTIONS

IVD: For in Vitro Diagnostic use only. Do not use expired reagents. Reagents with two different lot numbers should not be interchanged. For professional use. Follow Good Laboratory Practice (GLP) guidelines.

CAUTION: Human source samples are processed with this product. All human source samples must be treated as potentially infectious materials and must be handled in accordance with OSHA standards.

REAGENT STORAGE AND STABILITY⁶

Reagents are stable at 2-8°C until the expiration date stated on the label which is only for closed vials.

Once opened vials are stable for 60 days at 2-8°C in optimum conditions. On board stability is strongly related to auto analyzers' cooling specification and carry-over values.

Reagent stability and storage have been verified by using Clinical and Laboratory Standards Institute (CLSI) EP25-A protocol.

SPECIMEN STORAGE

Serum and plasma are collected according to the standard procedures. Serum and plasma are stable for: 2 days at 20-25°C, 7 days at 2-8°C, 1 year at -20°C

Unit Conversion:

mg/dL x 0.0113 = mmol/L

INTERFERING SUBSTANCES^{1, 2, 3, 12}

No significant interactions were observed for hemoglobin, conjugated bilirubin, up to the interferent concentration given in the table.

Interfering Substance and Concentration	Triglycerides Target (U/L)	N	Observed Recovery %
Hemoglobin ≤540 mg/dL	135.6	3	110
Bilirubin ≤4.11 mg/dL	171.4	3	94

The acceptable interference limit is set 10% below the highest interference concentration within ± 10% recovery of the target.

Interferences may affect the results due to medication or endogenous substances. These performance characteristics have been obtained by using an analyzer. Results may vary if a different instrument or a manual procedure is used.

CALIBRATION

Calibration stability is 30 days. Calibration stability depends on the application characteristics and cooling capacity of the autoanalyzer used.

At least two level controls must be run once in every 24 hours. Each laboratory should determine its own quality control scheme and procedures. If quality control results are not within acceptable limits, calibration is required

Note: Refer to the TC Matrix manual for further instructions on calibrating the instrument

MATERIALS NEEDED BUT NOT SUPPLIED WITH REAGENT KIT

Arcal Auto Calibrator

At least two levels of control material.

PROCEDURE

Settings for TC-Matrix 240/480

Test Name:	Triglyceride	R1:	200
Full Name:	Triglyceride	R2:	0
Pri. Wave:	505 nm	Sample volume:	2
Sec. Wave:	700 nm	Calibration Type:	2 Point Linear
Assay/ Point:	1-point End	K Value:	/
Start - End:	1 - 21	Point:	2
Decimal place:	1	Blank Type:	Reagent
Unit:	mg/dL	Point 0 (Blank) Con.:	0.0
Linearity Range:	2 - 1000	Point 1 (CAL) Con.:	Standard/
Correlation Factor:	1.0000 - 0.0000		Calibrator

REFERENCE INTERVAL (NORMAL VALUES) ⁷

Desired < 150 mg/dL

It is recommended that each laboratory establish its own normal range.

Reference interval has been verified by using CLSI EP28- A3c protocol.

PERFORMANCE CHARACTERISTICS

Limit of Detection (LoD): The limit of the test detection is 5 mg/dL.

Limit of Quantitation (LoQ) [LoQ values are based on Coefficient of Variation Percentage (CV) $\leq 20\%$];⁸ 10 mg/dL

LoD and LoQ values have been verified by using CLSI EP17-A protocol.

Precision⁹:

Repeatability (Within Run)

Mean Concentration (mg/dL)	SD	CV%	n
97.32	1.37	1.41	40
185.23	3.12	1.68	40

Reproducibility (Day- to- Day)

Mean Concentration (mg/dL)	SD	CV%	n
89.85	1.67	1.85	84
219.28	6.03	2.75	84

$\pm 10\%$ CV% differences can be observed between devices.

Precision Studies data have been verified by using CLSI EP05-A3 protocol.

Method Comparison^{10, 11}:

Correlation with a comparative method is $r = 0.99$

According to Passing-Bablok Fit:

Slope: 0.9973

Intercept: 0.981481

Linearity: The method is linear up to 1000 mg/dL.

For values above high linearity, dilute sample with 0.9% saline, repeat the test and multiply the result by the dilution factor.

Linearity may considerably vary depending on the instrument used.

REFERENCES

1. Tietz, N.W., Fundamentals of Clinical Chemistry, p. 940, W.B. Saunders Co., Philadelphia, 1987.
2. Tietz NW. Clinical Guide to Laboratory Tests. 2nd ed. Philadelphia, PA: WB Saunders Company; 1995,52.
3. Tietz NW. Clinical Guide to Laboratory Tests. 3rd ed. Philadelphia, PA: WB Saunders Company; 1995:88- 91.
4. Tietz NW, ed. Clinical Guide to Laboratory Tests. 3rd ed. Philadelphia: WB Saunders 1995:919.
5. Tietz Fundamentals of Clinical Chemistry. 5th ed. Burtis CA, Ashwood ER, eds. Philadelphia, PA: WB Saunders Company; 2001:605.
6. Clinical and Laboratory Standards Institute (CLSI). Evaluation of Stability of In Vitro Diagnostic Reagents; Approved Guideline. CLSI Document EP25-A. Wayne, PA: CLSI; 2009.
7. Clinical and Laboratory Standards Institute (CLSI). Defining, Establishing and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline — Third Edition. CLSI Document EP28-A3c. Wayne, PA: CLSI; 2010.
8. Clinical and Laboratory Standards Institute (CLSI). Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline. CLSI Document EP17-A. Wayne, PA: CLSI; Vol. 24 No. 34.
9. Clinical and Laboratory Standards Institute (CLSI). Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline — Third Edition. CLSI Document EP05-A3. Wayne, PA: CLSI; 2014

10. Passing-Bablok W et al. A General Regression Procedure for Method Transformation. J Clin Chem Clin Biochem 1988;26:783-79.
11. Clinical and Laboratory Standards Institute (CLSI). Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline—Second Edition; Approved Guideline CLSI Document EP09- A2. Wayne, PA: CLSI; Vol. 22 No. 19.
12. Clinical and Laboratory Standards Institute (CLSI). Interference Testing in Clinical Chemistry; Approved Guideline CLSI Document EP07. Wayne, PA: CLSI; 3rd Edition. CHERIAN G., SOLDIN ST. Clin. Chem. 27/5:748-752 (1981)
13. Trinder P. - J. Clin. Path. 22, 158 (1969);
14. Tietz Textbook of Clinical Chemistry, Second Edition, Burtis- Ashwood (1994).
15. Clinical and Laboratory Standards Institute (CLSI). Evaluation of Stability of In Vitro Diagnostic Reagents; Approved Guideline. CLSI Document EP25-A. Wayne, PA: CLSI; 2009.
16. Clinical and Laboratory Standards Institute (CLSI). Defining, Establishing and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline — Third Edition. CLSI Document EP28-A3c. Wayne, PA: CLSI; 2010.
17. Clinical and Laboratory Standards Institute (CLSI). Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline. CLSI Document EP17-A. Wayne, PA: CLSI; Vol. 24 No. 34.
18. Clinical and Laboratory Standards Institute (CLSI). Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline — Third Edition. CLSI Document EP05-A3. Wayne, PA: CLSI; 2014.
19. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem. 1982;28(10):2077.
20. Tietz NW. Clinical Guide to Laboratory Tests. 3rd edition. Philadelphia, PA: WB Saunders Company; 1995:610-611.
21. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem. 1969;6:24-27.
22. Young DS. Effects of Drugs on Clinical Laboratory Tests. 3rd ed. Washington: AACC Press; 1990.
23. Bucolo G., David M. - Clin. Chem. 19,476 (1973)
24. Clinical and Laboratory Standards Institute (formerly NCCLS). Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline-Second Edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2004. NCCLS Document EP05-A2.
25. McGowan M.W., Artiss J.D., Standbergh D.R., Zak B. Clin. Chem. 29, 538 (1983).

T532- TC2/TC4:05/2024

Manufactured by:



TECO DIAGNOSTICS
1268 N. Lakeview Ave.
Anaheim, CA 92807
U.S.A.
Website: www.tecodiagnostics.com